Genprex

News

Genprex to Focus on Developing Immunogene Therapy, Start Lung Cancer Trials This Year

Genprex said that after receiving the US Food and Drug Administration’s fast track designation last month for its immunogene therapy Oncoprex in combination with the EGFR tyrosine kinase inhibitor (TKI) osimertinib (AstraZeneca’s Tagrisso), the clinical-stage gene therapy company is prioritizing development of this therapy combination for EGFR-mutated non-small cell lung cancer.

Read More

Genprex Regains Compliance with Nasdaq Minimum Bid Price Requirement

Genprex announced that it received notice from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule.

Read More

Genprex to Focus Its Clinical Efforts on Oncoprex™ in Combination Therapy with Osimertinib for Non-Small Cell Lung Cancer (NSCLC)

Genprex provides a clinical update and focus for its Oncoprex™ immunogene therapy program for 2020, prioritizing the development of Oncoprex in combination with osimertinib for the treatment of non-small cell lung cancer (NSCLC).

Read More

Genprex to Present at NobleCon16 Investor Conference

Mr. Rodney Varner, Chief Executive Officer of Genprex, will deliver an overview of the Company and provide updates on its product pipeline, including the recent Fast Track Designation received from the Food and Drug Administration for its Oncoprex™ immunogene therapy in combination with AstraZeneca’s Tagrisso®.

Read More

Independent Researchers Find Genprex’s TUSC2 May Be a Novel Target and Biomarker for Thyroid Cancer Therapy

The study highlights the possibility that TUSC2 may also be effective in thyroid cancer therapy and adds to the growing body of research on TUSC2 beyond the non-small lung cell cancer indication the Company is initially pursuing

Read More

Genprex, Inc. Announces Closing of $8 Million At-The-Market Common Stock Offering

Capital raise follows recent Fast Track Designation by the FDA for Company’s Oncoprex™ imunogene therapy for NSCLC in combination therapy with AstraZeneca’s Tagrisso®

Read More

Genprex Wins FDA Fast Track Status for its Oncoprex Therapy in Combination with AstraZeneca’s Tagrisso

Genprex Inc (NASDAQ:GNPX) announced that the US Food and Drug Administration has granted Fast Track Designation for its Oncoprex immunogene therapy to treat lung cancer.

Read More

FDA Grants Fast Track Designation to Oncoprex Combination for NSCLC

Oncoprex in combination with Tagrisso received fast track designation from the Food and Drug Administration to treat patients with non-small cell lung cancer.

Read More

FDA Grants Fast Track Designation to Gene Therapy Combination in EGFR-Mutant NSCLC

The FDA has granted a Fast Track Designation to the immune-gene therapy Oncoprex in combination with the EGFR inhibitor osimertinib (Tagrisso) for the treatment of patients with EGFR-mutant non–small cell lung cancer (NSCLC) who have progressed after treatment with osimertinib alone, according to a press release from Genprex, Inc, developer of the therapeutic.

Read More

Genprex, Inc. Prices $8,000,000 Common Stock Offering Priced At-The-Market

Genprex today announced it has entered into securities purchase agreements with institutional investors for the purchase and sale of 7,620,000 shares of common stock, par value $0.001 per share at an offering price of $1.05 per share, pursuant to a registered direct offering, priced at-the-market under Nasdaq rules.

Read More